Symbicort in Chronic Obstruktive Pulmonary Disease (SYMBIOSE)

AstraZeneca

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Study type: Observational

Funder types: Industry

Identifiers

NCT00612976

German PMS trial no.8

budesonide /formoterol

1312006001

Details and patient eligibility

About

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e.general practitioners and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.

Enrollment: 18,014 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with COPD treated with budesonide/formoterol

Exclusion criteria

• limitiations; possible risks; warnings; contraindications mentioned in the SPC.

Trial design

18,014 participants in 1 patient group

1

Description:

Patients with COPD treated with budesonide/formoterol